

TEST CHANGE

Paraneoplastic Reflexive Panel, CSF

3004517, PNSPAN CSF

Specimen Requirements:

Patient Preparation:

Collect: CSF.

Specimen Preparation: Transfer 2 mL CSF to an ARUP Standard Transport Tube. (Min:

1 mL).

Transport Temperature: Refrigerated

Unacceptable Conditions: Contaminated, heat-inactivated, hemolyzed, or lipemic

specimens

Remarks:

Stability: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Methodology: Semi-Quantitative Indirect Fluorescent Antibody/Qualitative

Immunoblot

Performed: Wed

Reported: 1-9 days

Note: Purkinje Cell (PCCA) antibody and Neuronal Nuclear (ANNA)

antibody IgG are screened by IFA. If the IFA screen is

indeterminate, then a Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be added. If the IFA screen is positive at 1:1 or greater, then a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be added. Additional charges apply. If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG

Effective Date: August 21, 2023

Titer by IFA will be added. Additional charges apply.

CPT Codes: 86255 x2; 84182 x2; if reflexed add 86256 and/or 84182 x4; if

reflexed add 86256

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Refer to report

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was



performed in a CLIA-certified laboratory and is intended for clinical purposes.

Reference Interval:

Test Number	Components	Reference Interval
	Paraneoplastic Abs (PCCA/ANNA) IgG, CSF	None Detected
	CV2.1 Ab IgG <u>CBA-IFA</u> Screen, CSF	Less than 1:1
	SOX1 Antibody, IgG by Immunoblot, CSF	Negative
	Amphiphysin Antibody, CSF	Negative

Effective Date: August 21, 2023